<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="dar13588" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Rev</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Rev</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">DAR</journal-id><journal-title-group><journal-title>Drug and Alcohol Review</journal-title></journal-title-group><issn pub-type="ppub">0959-5236</issn><issn pub-type="epub">1465-3362</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10107800</article-id><article-id pub-id-type="pmcid-ver">PMC10107800.1</article-id><article-id pub-id-type="pmcaid">10107800</article-id><article-id pub-id-type="pmcaiid">10107800</article-id><article-id pub-id-type="pmid">36524444</article-id><article-id pub-id-type="doi">10.1111/dar.13588</article-id><article-id pub-id-type="publisher-id">DAR13588</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Papers</subject></subj-group></article-categories><title-group><article-title>Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016&#8211;2019</article-title><alt-title alt-title-type="right-running-head">Client attributes by <styled-content style="fixed-case" toggle="no">ATS</styled-content> use frequency</alt-title><alt-title alt-title-type="left-running-head">Black et al.</alt-title></title-group><contrib-group><contrib id="dar13588-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Black</surname><given-names initials="E">Emma</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3936-2434</contrib-id><xref rid="dar13588-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dar13588-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="dar13588-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>emma.black@health.nsw.gov.au</email></address></contrib><contrib id="dar13588-cr-0002" contrib-type="author"><name name-style="western"><surname>Mammen</surname><given-names initials="K">Kristie</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2395-2998</contrib-id><xref rid="dar13588-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="dar13588-cr-0003" contrib-type="author"><name name-style="western"><surname>Deacon</surname><given-names initials="RM">Rachel M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0877-3089</contrib-id><xref rid="dar13588-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dar13588-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="dar13588-cr-0004" contrib-type="author"><name name-style="western"><surname>Ezard</surname><given-names initials="N">Nadine</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7495-8305</contrib-id><xref rid="dar13588-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="dar13588-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="dar13588-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="dar13588-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="dar13588-cr-0005" contrib-type="author"><name name-style="western"><surname>Mills</surname><given-names initials="L">Llewellyn</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5320-087X</contrib-id><xref rid="dar13588-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dar13588-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="dar13588-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="dar13588-cr-0006" contrib-type="author"><name name-style="western"><surname>Dunlop</surname><given-names initials="AJ">Adrian J.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2394-5966</contrib-id><xref rid="dar13588-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="dar13588-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="dar13588-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="dar13588-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="dar13588-cr-0007" contrib-type="author"><name name-style="western"><surname>Montebello</surname><given-names initials="M">Mark</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1776-3974</contrib-id><xref rid="dar13588-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="dar13588-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="dar13588-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="dar13588-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="dar13588-cr-0008" contrib-type="author"><name name-style="western"><surname>Reid</surname><given-names initials="D">David</given-names></name><xref rid="dar13588-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="dar13588-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="dar13588-cr-0009" contrib-type="author"><name name-style="western"><surname>Childs</surname><given-names initials="S">Steven</given-names></name><xref rid="dar13588-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="dar13588-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="dar13588-cr-0010" contrib-type="author"><name name-style="western"><surname>Bruno</surname><given-names initials="R">Raimondo</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6673-833X</contrib-id><xref rid="dar13588-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="dar13588-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="dar13588-cr-0011" contrib-type="author"><name name-style="western"><surname>Shakeshaft</surname><given-names initials="A">Anthony</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5472-0930</contrib-id><xref rid="dar13588-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="dar13588-cr-0012" contrib-type="author"><name name-style="western"><surname>Siefried</surname><given-names initials="KJ">Krista J.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6534-3325</contrib-id><xref rid="dar13588-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="dar13588-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="dar13588-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="dar13588-cr-0013" contrib-type="author"><name name-style="western"><surname>Farrell</surname><given-names initials="M">Michael</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7008-8130</contrib-id><xref rid="dar13588-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="dar13588-cr-0014" contrib-type="author"><name name-style="western"><surname>Holmes</surname><given-names initials="J">Jennifer</given-names></name><xref rid="dar13588-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="dar13588-cr-0015" contrib-type="author"><name name-style="western"><surname>Lintzeris</surname><given-names initials="N">Nicholas</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5229-8257</contrib-id><xref rid="dar13588-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dar13588-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="dar13588-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib></contrib-group><aff id="dar13588-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Drug and Alcohol Services, South Eastern Sydney Local Health District</institution>
<city>Sydney</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Specialty of Addiction Medicine</named-content>
<institution>The University of Sydney</institution>
<city>Sydney</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>National Drug and Alcohol Research Centre, UNSW Sydney</institution>
<city>Sydney</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Alcohol and Drug Service, St Vincent's Hospital</institution>
<city>Sydney</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>National Centre for Clinical Research on Emerging Drugs</institution>
<city>Sydney</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0006">
<label>
<sup>6</sup>
</label>
<institution>NSW Drug and Alcohol Clinical Research and Improvement Network, NSW Ministry of Health</institution>
<city>Sydney</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>Drug and Alcohol Clinical Services, Hunter New England Local Health District</institution>
<city>Newcastle</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">School of Medicine and Public Health</named-content>
<institution>College of Health &amp; Wellbeing, University of Newcastle</institution>
<city>Newcastle</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0009">
<label>
<sup>9</sup>
</label>
<institution>HMRI Healthcare Transformation Research Program</institution>
<city>Newcastle</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0010">
<label>
<sup>10</sup>
</label>
<institution>Drug and Alcohol Services, North Sydney Local Health District</institution>
<city>Sydney</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0011">
<label>
<sup>11</sup>
</label>
<institution>Drug and Alcohol Services, Illawarra and Shoalhaven Local Health District</institution>
<city>Wollongong</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0012">
<label>
<sup>12</sup>
</label>
<institution>Drug and Alcohol Services, Central Coast Local Health District</institution>
<city>Gosford</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">School of Psychological Sciences</named-content>
<institution>University of Tasmania</institution>
<city>Hobart</city>
<country country="AU">Australia</country>
</aff><aff id="dar13588-aff-0014">
<label>
<sup>14</sup>
</label>
<institution>Centre for Alcohol and other Drugs, NSW Ministry of Health</institution>
<city>Sydney</city>
<country country="AU">Australia</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Emma Black, Drug and Alcohol Services, South Eastern Sydney Local Health District, The Langton Centre, 591 South Dowling St, Surry Hills, NSW 2010, Australia.<break/>
Email: <email>emma.black@health.nsw.gov.au</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2023</year></pub-date><volume>42</volume><issue seq="170">2</issue><issue-id pub-id-type="pmc-issue-id">433603</issue-id><issue-id pub-id-type="doi">10.1111/dar.v42.2</issue-id><fpage>389</fpage><lpage>400</lpage><history><date date-type="rev-recd"><day>09</day><month>11</month><year>2022</year></date><date date-type="received"><day>06</day><month>7</month><year>2022</year></date><date date-type="accepted"><day>11</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>18</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-02 00:25:12.103"><day>02</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2022 The Authors. <italic toggle="yes">Drug and Alcohol Review</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="DAR-42-389.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:DAR-42-389.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" xlink:title="correction" vol="42" page="1860" journal-id="Drug Alcohol Rev" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11062065"><article-title>Correction to &#8216;Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016&#8211;2019&#8217;</article-title><volume>42</volume><issue seq="250">7</issue><date><day>22</day><month>8</month><year>2023</year></date><fpage>1860</fpage><lpage>1861</lpage><source>Drug and Alcohol Review</source><pub-id pub-id-type="doi">10.1111/dar.13731</pub-id><pub-id pub-id-type="pmcid">PMC11062065</pub-id><pub-id pub-id-type="pmid">37608433</pub-id></related-article><abstract><title>Abstract</title><sec id="dar13588-sec-0001"><title>Introduction</title><p>Amphetamine type substances (ATS) are commonly used by Australian alcohol and other drug service entrants. We describe demographic characteristics, patterns of ATS and other substance use, health and social conditions among clients entering New South Wales (NSW) public alcohol and other drug services.</p></sec><sec id="dar13588-sec-0002"><title>Methods</title><p>Retrospective cohort of 13,864 records across six health districts (2016&#8211;2019) for clients seeking substance use treatment. These districts service approximately 44% of the NSW population aged 15&#8201;years and over. Multivariate analysis was conducted on a subsample for whom full data were available (<italic toggle="no">N</italic>&#160;=&#160;9981). Data included NSW Minimum Data Set for drug and alcohol treatment services and Australian Treatment Outcomes Profile items.</p></sec><sec id="dar13588-sec-0003"><title>Results</title><p>Over the preceding 4&#8201;weeks, 77% (<italic toggle="no">n</italic>&#160;=&#160;10,610) of clients (<italic toggle="no">N</italic>&#160;=&#160;13,864) reported no recent ATS use, 15% (<italic toggle="no">n</italic>&#160;=&#160;2109) reported &#8216;low frequency&#8217; (1&#8211;12&#8201;days) and 8% (<italic toggle="no">n</italic>&#160;=&#160;1145) &#8216;high frequency&#8217; (13&#8211;28&#8201;days) use. ATS use was most common among people attending for ATS or opioids as primary drug of concern. A multinomial regression (<italic toggle="no">N</italic>&#160;=&#160;9981) identified that clients reporting recent arrest (aOR 1.74, 95% CI 1.36, 2.24), higher cannabis use frequency (aOR 1.01, 95% CI 1.00, 1.02), lower opioid use frequency (aOR 0.98, 95% CI 0.97, 0.99) and poorer quality of life (aOR 0.91, 95% CI 0.86, 0.97) were more likely to report &#8216;high frequency&#8217; rather than &#8216;low frequency&#8217; ATS use.</p></sec><sec id="dar13588-sec-0004"><title>Discussion and Conclusions</title><p>People who use ATS experience health and social issues that may require targeted responses. These should be integrated across all services, not only for clients with ATS as principal drug of concern.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dar13588-kwd-0001">amphetamine type stimulants</kwd><kwd id="dar13588-kwd-0002">drug and alcohol treatment</kwd><kwd id="dar13588-kwd-0003">electronic medical records</kwd><kwd id="dar13588-kwd-0004">methamphetamine</kwd><kwd id="dar13588-kwd-0005">routine outcome monitoring</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>National Centre for Clinical Research on Emerging Drugs</funding-source><award-id>NCRC03</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="2"/><page-count count="12"/><word-count count="7227"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.7 mode:remove_FC converted:17.04.2023</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dar13588-cit-9001"><string-name name-style="western"><surname>Black</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mammen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Deacon</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Ezard</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mills</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dunlop</surname><given-names>AJ</given-names></string-name>, et al. <article-title>Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016&#8211;2019</article-title>. <source>Drug Alcohol Rev</source>. <year>2023</year>;<volume>42</volume>(<issue>2</issue>):<fpage>389</fpage>&#8211;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1111/dar.13588</pub-id><pub-id pub-id-type="pmid">36524444</pub-id><pub-id pub-id-type="pmcid">PMC10107800</pub-id></mixed-citation>
</p><fn-group><fn id="dar13588-note-1002"><p>
<bold>Funding information</bold> National Centre for Clinical Research on Emerging Drugs, Grant/Award Number: NCRC03</p></fn></fn-group></notes></front><body id="dar13588-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="dar13588-blkfxd-0001" orientation="portrait"><caption><title>Key Points</title></caption><p>
<list list-type="order" id="dar13588-list-0001"><list-item id="dar13588-li-0001"><p>With almost 14,000 client records described and almost 10,000 records included for further multivariate analysis, this paper represents the largest examination to date of amphetamine type substance (ATS) use among alcohol and other drug treatment entrants in Australia.</p></list-item><list-item id="dar13588-li-0002"><p>Almost a quarter (24%) of all clients entering alcohol and other drug treatment had used ATS in the preceding 4&#8201;weeks, regardless of their principal drug of concern. One in 12 clients (8%) reported &#8216;high&#8217; frequency ATS use (&#8805;13&#8201;days in the past 28).</p></list-item><list-item id="dar13588-li-0003"><p>Thirty percent of people who identified ATS as their principal drug of concern did not report any ATS use in the 28&#8201;days prior to treatment entry.</p></list-item><list-item id="dar13588-li-0004"><p>Clients who reported arrest, higher rates of cannabis use, lower rates of opioid use (excludes opioid agonist treatments used as prescribed) and poorer quality of life were significantly more likely to report using at higher frequency (&#8805;13/28&#8201;days) than they were to report no or low frequency ATS use during this time period.</p></list-item><list-item id="dar13588-li-0005"><p>Treatment should be individualised and tailored for each client, rather than designed to only address the primary drug of concern for which clients seek treatment.</p></list-item></list>
</p></boxed-text>
</p><sec id="dar13588-sec-0007"><label>1</label><title>INTRODUCTION</title><p>Amphetamine use in the past year is reported by 0.5% of the world's adult population [<xref rid="dar13588-bib-0001" ref-type="bibr">1</xref>]. Globally, North America reports the greatest population prevalence of past year use (2.3% of the population aged 15&#8211;64&#8201;years), followed by Australia and New Zealand (1.3%) [<xref rid="dar13588-bib-0001" ref-type="bibr">1</xref>, <xref rid="dar13588-bib-0002" ref-type="bibr">2</xref>]. Many service classification systems capture data using the heading of &#8216;amphetamine type stimulants&#8217; (ATS) and in Australia, methamphetamine is the predominant substance within this category. Throughout this paper we use the term &#8216;ATS&#8217; except where cited sources specify otherwise.</p><p>The increased availability and use of methamphetamine has been associated with a concurrent increase in harms, and more recently these harms have plateaued or declined slightly [<xref rid="dar13588-bib-0003" ref-type="bibr">3</xref>, <xref rid="dar13588-bib-0004" ref-type="bibr">4</xref>]. Overall, emergency department presentations and public hospital admissions for methamphetamine use in New South Wales (NSW) remain substantially higher than they were a decade ago, as have the number of ATS&#8208;related deaths [<xref rid="dar13588-bib-0005" ref-type="bibr">5</xref>].</p><p>ATS have become the second most common principal drug of concern (PDOC) in clients attending publicly funded alcohol and other drug (AOD) treatment services in Australia based on the National Minimum Data Set (NMDS), after alcohol [<xref rid="dar13588-bib-0006" ref-type="bibr">6</xref>], with just over one&#8208;quarter (28%) of all completed treatment episodes in 2019&#8211;2020 listed ATS as the principal drug of concern [<xref rid="dar13588-bib-0007" ref-type="bibr">7</xref>]. This represents a three&#8208;fold increase from 2008&#8211;2009 (9.2%) [<xref rid="dar13588-bib-0006" ref-type="bibr">6</xref>, <xref rid="dar13588-bib-0008" ref-type="bibr">8</xref>]. ATS was identified as an additional drug of concern among a further 8% of treatment entrants, such that ATS was nominated as a problem drug in 36% of all treatment episodes [<xref rid="dar13588-bib-0007" ref-type="bibr">7</xref>]. However, it should be noted that NMDS data do not include privately funded treatment (including primary care&#8208;based opioid agonist treatment and private specialist AOD services), and only report &#8216;closed treatment episodes&#8217; (rather than including treatment that is ongoing) and hence may not accurately reflect the full picture of people entering AOD treatment in Australia. Until now, understanding of the patterns of substance use and characteristics of clients who use ATS and enter treatment in Australia has been limited to either small cohort studies (e.g., [<xref rid="dar13588-bib-0009" ref-type="bibr">9</xref>, <xref rid="dar13588-bib-0010" ref-type="bibr">10</xref>]), clinical trials of treatment for ATS dependence (e.g., see [<xref rid="dar13588-bib-0011" ref-type="bibr">11</xref>, <xref rid="dar13588-bib-0012" ref-type="bibr">12</xref>] for reviews), or relied upon information available in the routine NMDS collected by publicly funded AOD treatment services [<xref rid="dar13588-bib-0007" ref-type="bibr">7</xref>, <xref rid="dar13588-bib-0008" ref-type="bibr">8</xref>, <xref rid="dar13588-bib-0013" ref-type="bibr">13</xref>].</p><p>There are, however, a number of limitations to such data sources. Population&#8208;level data from the NMDS contains a relatively limited range of variables&#8212;for example, they do not contain details of recent substance use (beyond capturing which substances are identified as &#8216;drugs of concern&#8217;) nor of the health status of people entering treatment. While more detailed data are available from clinical trials and cohort studies, it is difficult to generalise from small study populations (sample sizes usually comprise &lt;200 people recruited from a small number of services) to the wider treatment&#8208;seeking population. The introduction of electronic medical records (eMR) into public sector agencies, accounting for the majority (62%) of NSW AOD treatment episodes [<xref rid="dar13588-bib-0007" ref-type="bibr">7</xref>], provides the capacity to better describe substance use, social and health conditions of large numbers of clients attending NSW AOD services. These data can provide services with information to assist with treatment planning, provision and workforce development.</p><sec id="dar13588-sec-0008"><label>1.1</label><title>
Aims
</title><p>This paper aims to examine:<list list-type="alpha-lower" id="dar13588-list-0002"><list-item id="dar13588-li-0006"><p>Is there a relationship between substance use, social conditions, health and wellbeing and having used ATS use in the 28&#8201;days prior to entering AOD treatment?; and</p></list-item><list-item id="dar13588-li-0007"><p>Is there an association between frequency of ATS use at treatment entry and substance use, social conditions, health and wellbeing?</p></list-item></list>
</p></sec></sec><sec sec-type="methods" id="dar13588-sec-0009"><label>2</label><title>METHODS</title><sec id="dar13588-sec-0010"><label>2.1</label><title>
Design
</title><p>Retrospective extract of eMR data for clients entering public&#8208;sector AOD treatment services in participating health districts in NSW.</p></sec><sec id="dar13588-sec-0011"><label>2.2</label><title>
Study population
</title><p>Six administrative health districts participated in the project, including four in metropolitan Sydney and two spanning regional districts. Overall, these districts provide services to approximately 44% (approximately 3.1&#160;million people) of the NSW population aged 15 and above [<xref rid="dar13588-bib-0014" ref-type="bibr">14</xref>]. Of the six participating districts, three operated specialist Stimulant Clinics, and all provided a range of community&#8208;based services and acute inpatient hospital services, but not longer&#8208;term residential rehabilitation programmes (usually provided by the non&#8208;government sector) [<xref rid="dar13588-bib-0015" ref-type="bibr">15</xref>, <xref rid="dar13588-bib-0016" ref-type="bibr">16</xref>, <xref rid="dar13588-bib-0017" ref-type="bibr">17</xref>, <xref rid="dar13588-bib-0018" ref-type="bibr">18</xref>].</p></sec><sec id="dar13588-sec-0012"><label>2.3</label><title>
Procedure
</title><p>Data managers at participating districts extracted data from eMR for all people who completed an Australian Treatment Outcomes Profile (ATOP) at entry to treatment (assessment ATOP) between 1 July 2016 and 30 June 2019. Data were de&#8208;identified onsite by the data manager before secure transfer to the lead site.</p></sec><sec id="dar13588-sec-0013"><label>2.4</label><title>
Measures
</title><sec id="dar13588-sec-0014"><label>2.4.1</label><title>
The <styled-content style="fixed-case" toggle="no">NSW</styled-content> Minimum Data Set&#8212;Drug and alcohol treatment services
</title><p>The NSW MDS DATS is a routine, ongoing data collection compiled by NSW Health AOD treatment services [<xref rid="dar13588-bib-0019" ref-type="bibr">19</xref>] and contributes to the NMDS. It records information about client and treatment characteristics and activities within publicly funded AOD treatment programmes. Items included in the present study were age, sex, country of birth, Aboriginal and/or Torres Strait Islander Status and preferred language.</p></sec><sec id="dar13588-sec-0015"><label>2.4.2</label><title>
Australian Treatment Outcomes Profile
</title><p>The ATOP is a 22&#8208;item, validated, client&#8208;reported scale that assesses a range of domains over the preceding 28&#8201;days [<xref rid="dar13588-bib-0020" ref-type="bibr">20</xref>, <xref rid="dar13588-bib-0021" ref-type="bibr">21</xref>, <xref rid="dar13588-bib-0022" ref-type="bibr">22</xref>], including recent number of days' substance use, injecting behaviour, vocational engagement (days of paid work or study in past 28), housing stress (homeless or at risk of eviction), arrest, whether they are living with children and whether they have experienced violence as victim and/or perpetrator. Clients also rate their physical health, psychological health and quality of life from 0 (poor) to 10 (good), with scores of 5 or below identifying significant concerns in these domains [<xref rid="dar13588-bib-0022" ref-type="bibr">22</xref>].</p><p>All available independent variables from the ATOP and demographic descriptors from the NSW MDS DATS in eMR were included in the analyses because, by virtue of their inclusion in the NSW MDS DATS and ATOP, all were considered to be clinically relevant. These were as follows:<list list-type="bullet" id="dar13588-list-0003"><list-item id="dar13588-li-0008"><p>Numeric variables: age, number of days of substance use in the past 28&#8201;days (alcohol, benzodiazepines, cannabis, cocaine and opioids [excluding prescribed opioid agonist treatment]), self&#8208;ratings (scale 0&#8211;10) of psychological health, physical health and quality of life.</p></list-item><list-item id="dar13588-li-0009"><p>Binary categorical variables: sex (male or female, as only binary information was available), Australian&#8208;born, Aboriginal and/or Torres Strait Islander status, English preferred language, any recent work/study, any housing stress, any violence (as victim and/or perpetrator), living with a child under 5&#8201;years of age, being arrested and any injecting drug use.</p></list-item></list>
</p></sec></sec><sec id="dar13588-sec-0016"><label>2.5</label><title>
Data analysis
</title><p>All analyses were conducted using SPSS, Version 26 [<xref rid="dar13588-bib-0023" ref-type="bibr">23</xref>]. The effect of the above independent variables on two dependent/outcome variables were tested: any ATS use (binary categorical: no ATS use in previous 28&#8201;days [reference] vs. &gt;0&#8201;days' use) and frequency of ATS use (three&#8208;level categorical: &#8216;no&#8217; ATS use [0&#8201;days in previous 28] vs. &#8216;low frequency&#8217; ATS use [1&#8211;12&#8201;days used] vs. &#8216;high frequency&#8217; ATS use [13&#8211;28&#8201;days] [see [<xref rid="dar13588-bib-0022" ref-type="bibr">22</xref>]]). Transformation of frequency of ATS use from a bounded count variable (days of ATS use in the previous 28) to a categorical variable was based on its being bi&#8208;modally distributed, thus violating the normality assumption of linear regression. Categorisation into the three levels &#8216;no&#8217;, &#8216;low frequency&#8217; and &#8216;high frequency&#8217; was based on statistical analyses and consultation with clinicians and consumers conducted by the authors (see [<xref rid="dar13588-bib-0024" ref-type="bibr">24</xref>]).</p><p>Univariate binary logistic regressions, chi squares&#160;and Welch's t tests were conducted to examine the relationships between each of the independent variables listed above and the binary dependent variable any ATS use. Following these univariate analyses, a multivariate multinomial logistic regression was conducted on the subsample of full data (<italic toggle="yes">n</italic>&#160;=&#160;9981) to identify factors associated with frequency of ATS use. Due to the large sample size, we used a significance level of <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, with the Benjamini&#8211;Hochberg correction for multiple tests.</p></sec></sec><sec sec-type="results" id="dar13588-sec-0017"><label>3</label><title>RESULTS</title><sec id="dar13588-sec-0018"><label>3.1</label><title>
Participant flow
</title><p>Selection of data for inclusion are outlined in Figure&#160;<xref rid="dar13588-fig-0001" ref-type="fig">1</xref>. Where a person commenced treatment on more than one occasion over the 5&#8208;year period, data from the first assessment were used. We were unable to identify when people attended services in more than one district, so in these instances, clients may have been double counted. Other than subsequent treatment episodes, the primary reason for exclusion of a record was because information regarding recent ATS use was not recorded (<italic toggle="yes">n</italic>&#160;=&#160;1097); other exclusions are outlined in Figure&#160;<xref rid="dar13588-fig-0001" ref-type="fig">1</xref>.</p><fig position="float" fig-type="FIGURE" id="dar13588-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Flowchart of the steps in selection of records for analysis. ATS, amphetamine type substances; OAT, opioid agonist therapy; PDOC, principal drug of concern</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="DAR-42-389-g002.jpg"/></fig></sec><sec id="dar13588-sec-0019"><label>3.2</label><title>
What are the characteristics of clients entering treatment by <styled-content style="fixed-case" toggle="no">ATS</styled-content> use?
</title><p>Figure&#160;<xref rid="dar13588-fig-0002" ref-type="fig">2</xref> shows a bimodal distribution of ATS use frequency (number of days used in past 28) at treatment entry, with 10,610 reporting no ATS use (76.5%), 2109 (15.1%) reporting low frequency and 1145 (8.3%) reporting high frequency use. This profile was similar by sex.</p><fig position="float" fig-type="FIGURE" id="dar13588-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Frequency of amphetamine type substances (ATS) use in 28&#8201;days preceding assessment, among all clients entering treatment, <italic toggle="yes">N</italic>&#160;=&#160;13,864, July 2016&#8211;June 2019</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="DAR-42-389-g001.jpg"/></fig><p>Univariate tests demonstrated significant differences between clients who did and did not report recent ATS use (Table&#160;<xref rid="dar13588-tbl-0001" ref-type="table">1</xref>). In particular, clients reporting recent ATS use reported significantly more housing stress, more violence and more arrests. Clients reporting recent ATS use also had greater odds of reporting recent injecting and recent cannabis, non&#8208;opioid agonist therapy (OAT) opioid and (daily) tobacco use. Just under half (46%) were in treatment for ATS as their PDOC, and almost one&#8208;quarter (23%) were in treatment for opioids as their PDOC. Aboriginal and/or Torres Strait Islander status was not included in inferential analyses as the study had not met ethical requirements for research specific to Aboriginal and Torres Strait Islander populations.</p><table-wrap position="float" id="dar13588-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Demographics, risk factors and other substance use in people entering treatment, by frequency of ATS use (none/any), July 2016&#8211;June 2019, <italic toggle="no">N</italic>&#160;=&#160;13,864</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="2" align="left" char="/" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">No ATS use past 28&#8201;days, <italic toggle="yes">N</italic>&#160;=&#160;10,610</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Any ATS use past 28&#8201;days, <italic toggle="yes">N</italic>&#160;=&#160;3254<xref rid="dar13588-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Univariate test<xref rid="dar13588-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th colspan="2" align="left" char="/" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Overall, <italic toggle="yes">N</italic>&#160;=&#160;13,864</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Demographics</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Age (mean, SD, range)</td><td align="left" valign="top" rowspan="1" colspan="1">40.4</td><td align="left" valign="top" rowspan="1" colspan="1">12.7, 14&#8211;88</td><td align="left" valign="top" rowspan="1" colspan="1">35.22</td><td align="left" valign="top" rowspan="1" colspan="1">9.6, 14&#8211;71</td><td align="left" valign="top" rowspan="1" colspan="1">Welch's <italic toggle="yes">t</italic>(7047)&#160;=&#160;24.90, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Glass' <italic toggle="yes">d</italic>&#160;=&#160;0.54</td><td align="left" valign="top" rowspan="1" colspan="1">39.2</td><td align="left" valign="top" rowspan="1" colspan="1">12.2, 14&#8211;88</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sex (male)</td><td align="left" valign="top" rowspan="1" colspan="1">7006</td><td align="left" valign="top" rowspan="1" colspan="1">66.0</td><td align="left" valign="top" rowspan="1" colspan="1">2211</td><td align="left" valign="top" rowspan="1" colspan="1">67.9</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;1.09 (95% CI 1.00, 1.19)</td><td align="left" valign="top" rowspan="1" colspan="1">9217</td><td align="left" valign="top" rowspan="1" colspan="1">66.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Australian born</td><td align="left" valign="top" rowspan="1" colspan="1">8376<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">85.3<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2549<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">91.1<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;1.78 (95% CI 1.54, 2.05)</td><td align="left" valign="top" rowspan="1" colspan="1">10,925<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">86.6<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Aboriginal and/or Torres Strait Islander</td><td align="left" valign="top" rowspan="1" colspan="1">1169<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">12.0<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">477<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">17.2<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">1646<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">13.1<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">English pref. language</td><td align="left" valign="top" rowspan="1" colspan="1">9692<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">98.4<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2764<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">98.4<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">12,456<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">98.4<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Principal drug of concern</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Alcohol</td><td align="left" valign="top" rowspan="1" colspan="1">5292</td><td align="left" valign="top" rowspan="1" colspan="1">50.0</td><td align="left" valign="top" rowspan="1" colspan="1">302</td><td align="left" valign="top" rowspan="1" colspan="1">9.3</td><td rowspan="5" align="left" valign="top" colspan="1">
<p>
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#160;=&#160;3748(4), <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</p>
<p>Cramer's <italic toggle="yes">V</italic>&#160;=&#160;0.52, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">5594</td><td align="left" valign="top" rowspan="1" colspan="1">40.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ATS</td><td align="left" valign="top" rowspan="1" colspan="1">625</td><td align="left" valign="top" rowspan="1" colspan="1">5.9</td><td align="left" valign="top" rowspan="1" colspan="1">1496</td><td align="left" valign="top" rowspan="1" colspan="1">46.1</td><td align="left" valign="top" rowspan="1" colspan="1">2121</td><td align="left" valign="top" rowspan="1" colspan="1">15.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cannabis</td><td align="left" valign="top" rowspan="1" colspan="1">1632</td><td align="left" valign="top" rowspan="1" colspan="1">15.4</td><td align="left" valign="top" rowspan="1" colspan="1">323</td><td align="left" valign="top" rowspan="1" colspan="1">10.0</td><td align="left" valign="top" rowspan="1" colspan="1">1955</td><td align="left" valign="top" rowspan="1" colspan="1">14.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Opioids</td><td align="left" valign="top" rowspan="1" colspan="1">2279</td><td align="left" valign="top" rowspan="1" colspan="1">21.5</td><td align="left" valign="top" rowspan="1" colspan="1">748</td><td align="left" valign="top" rowspan="1" colspan="1">23.1</td><td align="left" valign="top" rowspan="1" colspan="1">3027</td><td align="left" valign="top" rowspan="1" colspan="1">21.9</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other/unclear</td><td align="left" valign="top" rowspan="1" colspan="1">755</td><td align="left" valign="top" rowspan="1" colspan="1">7.1</td><td align="left" valign="top" rowspan="1" colspan="1">374</td><td align="left" valign="top" rowspan="1" colspan="1">11.5</td><td align="left" valign="top" rowspan="1" colspan="1">1129</td><td align="left" valign="top" rowspan="1" colspan="1">8.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Social conditions</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Work/study</td><td align="left" valign="top" rowspan="1" colspan="1">3549<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">36.2<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">724<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">24.1<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;0.56 (95% CI 0.51, 0.62)</td><td align="left" valign="top" rowspan="1" colspan="1">4273<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">33.4<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Housing stress</td><td align="left" valign="top" rowspan="1" colspan="1">1140</td><td align="left" valign="top" rowspan="1" colspan="1">10.8</td><td align="left" valign="top" rowspan="1" colspan="1">888</td><td align="left" valign="top" rowspan="1" colspan="1">27.5</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;3.12 (95% CI 2.83, 3.45)</td><td align="left" valign="top" rowspan="1" colspan="1">2028</td><td align="left" valign="top" rowspan="1" colspan="1">14.7</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Living with child &lt;5&#8201;years</td><td align="left" valign="top" rowspan="1" colspan="1">1094</td><td align="left" valign="top" rowspan="1" colspan="1">10.5</td><td align="left" valign="top" rowspan="1" colspan="1">220</td><td align="left" valign="top" rowspan="1" colspan="1">6.9</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;0.63 (95% CI 0.54, 0.74)</td><td align="left" valign="top" rowspan="1" colspan="1">1314</td><td align="left" valign="top" rowspan="1" colspan="1">9.6</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Arrest</td><td align="left" valign="top" rowspan="1" colspan="1">934</td><td align="left" valign="top" rowspan="1" colspan="1">8.9</td><td align="left" valign="top" rowspan="1" colspan="1">639</td><td align="left" valign="top" rowspan="1" colspan="1">19.8</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;2.54 (95% CI 2.27, 2.83)</td><td align="left" valign="top" rowspan="1" colspan="1">1573</td><td align="left" valign="top" rowspan="1" colspan="1">11.4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Violence to self</td><td align="left" valign="top" rowspan="1" colspan="1">598</td><td align="left" valign="top" rowspan="1" colspan="1">5.7</td><td align="left" valign="top" rowspan="1" colspan="1">368</td><td align="left" valign="top" rowspan="1" colspan="1">11.4</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;2.14 (95% CI 1.86, 2.45)</td><td align="left" valign="top" rowspan="1" colspan="1">966</td><td align="left" valign="top" rowspan="1" colspan="1">7.0</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Violence to others</td><td align="left" valign="top" rowspan="1" colspan="1">631</td><td align="left" valign="top" rowspan="1" colspan="1">6.0</td><td align="left" valign="top" rowspan="1" colspan="1">433</td><td align="left" valign="top" rowspan="1" colspan="1">13.4</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;2.43 (95% CI 2.14, 2.77)</td><td align="left" valign="top" rowspan="1" colspan="1">1064</td><td align="left" valign="top" rowspan="1" colspan="1">7.8</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any violence</td><td align="left" valign="top" rowspan="1" colspan="1">989</td><td align="left" valign="top" rowspan="1" colspan="1">9.4</td><td align="left" valign="top" rowspan="1" colspan="1">611</td><td align="left" valign="top" rowspan="1" colspan="1">18.9</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;2.25 (95% CI 2.01, 2.51)</td><td align="left" valign="top" rowspan="1" colspan="1">1600</td><td align="left" valign="top" rowspan="1" colspan="1">11.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Substance use (any)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any alcohol use</td><td align="left" valign="top" rowspan="1" colspan="1">6658</td><td align="left" valign="top" rowspan="1" colspan="1">63.2</td><td align="left" valign="top" rowspan="1" colspan="1">1627</td><td align="left" valign="top" rowspan="1" colspan="1">51.8</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;0.63 (95% CI 0.58, 0.68)</td><td align="left" valign="top" rowspan="1" colspan="1">8195</td><td align="left" valign="top" rowspan="1" colspan="1">60.6</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median days use<xref rid="dar13588-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref> (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">7&#8211;28</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">2&#8211;20</td><td align="left" valign="top" rowspan="1" colspan="1">Welch's <italic toggle="yes">t</italic>(2524)&#160;=&#160;18.90, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Glass' <italic toggle="yes">d</italic>&#160;=&#160;0.52</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">4&#8211;28</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any ATS use<xref rid="dar13588-note-0006" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">3254</td><td align="left" valign="top" rowspan="1" colspan="1">100.0</td><td align="left" valign="top" rowspan="1" colspan="1">&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">3254</td><td align="left" valign="top" rowspan="1" colspan="1">23.5</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median days use<xref rid="dar13588-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref> (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">2&#8211;19</td><td align="left" valign="top" rowspan="1" colspan="1">&#8208;</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">2&#8211;19</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any benzodiazepine use</td><td align="left" valign="top" rowspan="1" colspan="1">1620</td><td align="left" valign="top" rowspan="1" colspan="1">15.5</td><td align="left" valign="top" rowspan="1" colspan="1">772<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">25.7<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;1.88 (95% CI 1.7&#8211;2.07)</td><td align="left" valign="top" rowspan="1" colspan="1">2392</td><td align="left" valign="top" rowspan="1" colspan="1">17.8</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median days use<xref rid="dar13588-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref> (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">4&#8211;28</td><td align="left" valign="top" rowspan="1" colspan="1">8<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2&#8211;28<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Welch's <italic toggle="yes">t</italic>(1552)&#160;=&#160;5.66, <italic toggle="yes">p</italic> &lt;, Glass' <italic toggle="yes">d</italic>&#160;=&#160;0.25</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">3&#8211;28</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any cannabis use</td><td align="left" valign="top" rowspan="1" colspan="1">3014</td><td align="left" valign="top" rowspan="1" colspan="1">28.8</td><td align="left" valign="top" rowspan="1" colspan="1">1737</td><td align="left" valign="top" rowspan="1" colspan="1">55.4</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;3.07 (95% CI 2.83, 3.33)</td><td align="left" valign="top" rowspan="1" colspan="1">4751</td><td align="left" valign="top" rowspan="1" colspan="1">34.9</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median days use<xref rid="dar13588-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref> (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">8&#8211;28</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">7&#8211;28</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">8&#8211;28</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any cocaine use</td><td align="left" valign="top" rowspan="1" colspan="1">441</td><td align="left" valign="top" rowspan="1" colspan="1">4.3</td><td align="left" valign="top" rowspan="1" colspan="1">262<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">9.0<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;2.20 (95% CI 1.88, 2.58)</td><td align="left" valign="top" rowspan="1" colspan="1">703<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">5.4<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median days use<xref rid="dar13588-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref> (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">1&#8211;10</td><td align="left" valign="top" rowspan="1" colspan="1">2<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1&#8211;4<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Welch's <italic toggle="yes">t</italic>(676) = 5.91, <italic toggle="yes">p</italic> &lt; 0.001, Glass' <italic toggle="yes">d</italic> = 0.54</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">1&#8211;8</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any non&#8208;OAT opioid use</td><td align="left" valign="top" rowspan="1" colspan="1">1460</td><td align="left" valign="top" rowspan="1" colspan="1">14.1</td><td align="left" valign="top" rowspan="1" colspan="1">792<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">26.5<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;2.19 (95% CI 1.99&#8211;2.41)</td><td align="left" valign="top" rowspan="1" colspan="1">2252</td><td align="left" valign="top" rowspan="1" colspan="1">16.9</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median days use<xref rid="dar13588-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref> (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">28</td><td align="left" valign="top" rowspan="1" colspan="1">13&#8211;28</td><td align="left" valign="top" rowspan="1" colspan="1">20<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">6&#8211;28<xref rid="dar13588-note-0008" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Welch's <italic toggle="yes">t</italic>(1499)&#160;=&#160;7.67, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Glass' <italic toggle="yes">d</italic>&#160;=&#160;&#8722;0.33</td><td align="left" valign="top" rowspan="1" colspan="1">27</td><td align="left" valign="top" rowspan="1" colspan="1">9&#8211;28</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any injecting</td><td align="left" valign="top" rowspan="1" colspan="1">712</td><td align="left" valign="top" rowspan="1" colspan="1">7.0</td><td align="left" valign="top" rowspan="1" colspan="1">1561</td><td align="left" valign="top" rowspan="1" colspan="1">50.3</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;13.52 (95% CI 12.19, 14.99)</td><td align="left" valign="top" rowspan="1" colspan="1">2273</td><td align="left" valign="top" rowspan="1" colspan="1">17.1</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median days injected<xref rid="dar13588-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref> (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">25</td><td align="left" valign="top" rowspan="1" colspan="1">8&#8211;28</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">4&#8211;28</td><td align="left" valign="top" rowspan="1" colspan="1">Welch's <italic toggle="yes">t</italic>(1367)&#160;=&#160;8.48, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Glass' <italic toggle="yes">d</italic>&#160;=&#160;0.39</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">4&#8211;28</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Daily tobacco</td><td align="left" valign="top" rowspan="1" colspan="1">6725</td><td align="left" valign="top" rowspan="1" colspan="1">65.2</td><td align="left" valign="top" rowspan="1" colspan="1">2665</td><td align="left" valign="top" rowspan="1" colspan="1">85.3</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;3.09 (95% CI 2.78, 3.44)</td><td align="left" valign="top" rowspan="1" colspan="1">9390</td><td align="left" valign="top" rowspan="1" colspan="1">69.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Health and wellbeing</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">M</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">SD, range</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">M</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">SD, range</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">M</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">SD, range</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Psychological health</td><td align="left" valign="top" rowspan="1" colspan="1">5.4<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.2, 0&#8211;10</td><td align="left" valign="top" rowspan="1" colspan="1">4.9<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.2, 0&#8211;10<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Welch's <italic toggle="yes">t</italic>(4739)&#160;=&#160;10.72, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Glass' <italic toggle="yes">d</italic>&#160;=&#160;0.23</td><td align="left" valign="top" rowspan="1" colspan="1">5.3<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.2, 0&#8211;10<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">% scoring 5 or below<xref rid="dar13588-note-0011" ref-type="table-fn">
<sup>h</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;=&#160;4750</td><td align="left" valign="top" rowspan="1" colspan="1">51.0%</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;=&#160;1745</td><td align="left" valign="top" rowspan="1" colspan="1">61.6%</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;0.65 (95% CI 0.60, 0.71)</td><td align="left" valign="top" rowspan="1" colspan="1">53.5%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Physical health</td><td align="left" valign="top" rowspan="1" colspan="1">6.0<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.1, 0&#8211;10</td><td align="left" valign="top" rowspan="1" colspan="1">5.8<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.0, 0&#8211;10<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Welch's <italic toggle="yes">t</italic>(4907)&#160;=&#160;4.15, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Glass' <italic toggle="yes">d</italic>&#160;=&#160;0.09</td><td align="left" valign="top" rowspan="1" colspan="1">6.0<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.1, 0&#8211;10<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">% scoring 5 or below<xref rid="dar13588-note-0011" ref-type="table-fn">
<sup>h</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;=&#160;3683</td><td align="left" valign="top" rowspan="1" colspan="1">39.6%</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;=&#160;1268</td><td align="left" valign="top" rowspan="1" colspan="1">44.8%</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;0.81 (95% CI 0.74, 0.88)</td><td align="left" valign="top" rowspan="1" colspan="1">40.8%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Overall quality of life</td><td align="left" valign="top" rowspan="1" colspan="1">5.8<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.3, 0&#8211;10</td><td align="left" valign="top" rowspan="1" colspan="1">5.1<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.2, 0&#8211;10<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Welch's <italic toggle="yes">t</italic>(4724)&#160;=&#160;14.22, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Glass' <italic toggle="yes">d</italic>&#160;=&#160;0.31</td><td align="left" valign="top" rowspan="1" colspan="1">5.6<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.3, 0&#8211;10<xref rid="dar13588-note-0009" ref-type="table-fn">
<sup>f</sup>
</xref>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">% scoring 5 or below<xref rid="dar13588-note-0011" ref-type="table-fn">
<sup>g</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;=&#160;4167</td><td align="left" valign="top" rowspan="1" colspan="1">45.0%</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#160;=&#160;1639</td><td align="left" valign="top" rowspan="1" colspan="1">58.2%<xref rid="dar13588-note-0010" ref-type="table-fn">
<sup>g</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">OR&#160;=&#160;0.59 (95% CI 0.54, 0.64)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="dar13588-ntgp-0001"><fn id="dar13588-note-0001"><p>
<italic toggle="yes">Note</italic>: Due to rounding, percentages may not total 100. Values below 0.5 not rounded. See Tables&#160;<xref rid="dar13588-supitem-0001" ref-type="supplementary-material">S1&#8211;S4</xref> for details, including univariate analyses, of these independent variables by frequency of ATS use (no, &#8216;low frequency&#8217; and &#8216;high frequency&#8217;).</p></fn><fn id="dar13588-note-0002"><p>Abbreviations: ATS, amphetamine type substances; CI, confidence interval; IQR, interquartile range; OAT, opioid agonist therapy; OR, odds ratio.</p></fn><fn id="dar13588-note-0003"><label>
<sup>a</sup>
</label><p>Combines &#8216;low frequency&#8217; and &#8216;high frequency&#8217; groups.</p></fn><fn id="dar13588-note-0004"><label>
<sup>b</sup>
</label><p>Welch's <italic toggle="yes">t</italic> test and Glass' delta used where heterogeneity of variance detected.</p></fn><fn id="dar13588-note-0005"><label>
<sup>c</sup>
</label><p>Among those who had used the substance in preceding 28&#8201;days.</p></fn><fn id="dar13588-note-0006"><label>
<sup>d</sup>
</label><p>
Complete data for this item was an eligibility criterion (people with missing data were excluded from these results)</p></fn><fn id="dar13588-note-0008"><label>
<sup>e</sup>
</label><p>5&#8211;10% missing data.</p></fn><fn id="dar13588-note-0009"><label>f</label><p>11&#8211;15% missing data.</p></fn><fn id="dar13588-note-0010"><label>
<sup>g</sup>
</label><p>16&#8211;20% missing data.</p></fn><fn id="dar13588-note-0011"><label>
<sup>h</sup>
</label><p>Indicates clinically significant problems in this life area.</p></fn></table-wrap-foot></table-wrap><p>Further testing was conducted to identify any differences between clients by frequency of ATS use (no use, &#8216;low frequency&#8217; [1&#8211;12&#8201;days] and &#8216;high frequency&#8217; [13&#8211;28&#8201;days] use) and indicated many significant differences between the groups at the univariate level (Tables&#160;<xref rid="dar13588-supitem-0001" ref-type="supplementary-material">S2&#8211;S4</xref>, Supporting Information). A multinomial regression was then conducted to examine the relationship between these variables and ATS use frequency.</p></sec><sec id="dar13588-sec-0020"><label>3.3</label><title>
Examining the association between <styled-content style="fixed-case" toggle="no">ATS</styled-content> (no, low and high frequency use) and other factors
</title><p>The multivariate multinomial logistic regression (<italic toggle="yes">N</italic>&#160;=&#160;9981) demonstrated several factors were associated with ATS use (Table&#160;<xref rid="dar13588-tbl-0002" ref-type="table">2</xref>). Addition of the independent variables to a model that contained only the intercept significantly improved the fit between model and data, <italic toggle="yes">&#967;</italic>
<sup>2</sup>(df&#160;=&#160;32)&#160;=&#160;3175.96, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. Significant contributions were made by a large number of variables, as described in the following sections. Demographic characteristics, social conditions and substance use patterns of this subsample (<italic toggle="yes">N</italic>&#160;=&#160;9981) are shown in Table&#160;<xref rid="dar13588-supitem-0001" ref-type="supplementary-material">S5</xref>.</p><table-wrap position="float" id="dar13588-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Multivariable multinomial logistic regression: relationship of demographic, social conditions and substance use to recent amphetamine use (categories: no/low frequency/high frequency) (<italic toggle="no">N</italic>&#160;=&#160;9981)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">&#8216;Low frequency&#8217; versus no ATS use</th><th colspan="3" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">&#8216;High frequency&#8217; versus no ATS use</th><th colspan="3" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">&#8216;High frequency&#8217; versus &#8216;low frequency&#8217; ATS use</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.96</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.95&#8211;0.97</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.95</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.95&#8211;0.96</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">0.99</td><td align="char" valign="top" rowspan="1" colspan="1">0.99&#8211;1.00</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (male)</td><td align="char" valign="top" rowspan="1" colspan="1">1.17</td><td align="char" valign="top" rowspan="1" colspan="1">1.01&#8211;1.34</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">0.94</td><td align="char" valign="top" rowspan="1" colspan="1">0.78&#8211;1.13</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">0.80</td><td align="char" valign="top" rowspan="1" colspan="1">0.66&#8211;0.98</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Work/study</td><td align="char" valign="top" rowspan="1" colspan="1">0.91</td><td align="char" valign="top" rowspan="1" colspan="1">0.79&#8211;1.06</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.79</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.64&#8211;0.98</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">0.87</td><td align="char" valign="top" rowspan="1" colspan="1">0.69&#8211;1.09</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Housing stress</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.53</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.29&#8211;1.81</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.73</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.40&#8211;2.13</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">1.13</td><td align="char" valign="top" rowspan="1" colspan="1">0.92&#8211;1.40</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Living with child &lt;5&#8201;years</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.68</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.54&#8211;0.86</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0015" ref-type="table-fn">*</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.64</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.46&#8211;0.89</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0015" ref-type="table-fn">*</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">0.95</td><td align="char" valign="top" rowspan="1" colspan="1">0.66&#8211;1.36</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Arrest</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.38</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.12&#8211;1.70</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0015" ref-type="table-fn">*</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>2.41</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.89&#8211;3.06</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.74</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.36&#8211;2.24</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Any violence</td><td align="char" valign="top" rowspan="1" colspan="1">1.29</td><td align="char" valign="top" rowspan="1" colspan="1">1.06&#8211;1.58</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.46</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.14&#8211;1.85</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0015" ref-type="table-fn">*</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">1.13</td><td align="char" valign="top" rowspan="1" colspan="1">0.88&#8211;1.45</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol days</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.97</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.97&#8211;0.98</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.96</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.95&#8211;0.97</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">0.99</td><td align="char" valign="top" rowspan="1" colspan="1">0.98&#8211;1.00</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Benzodiazepine days</td><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" valign="top" rowspan="1" colspan="1">0.99&#8211;1.01</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" valign="top" rowspan="1" colspan="1">0.99&#8211;1.01</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" valign="top" rowspan="1" colspan="1">0.99&#8211;1.01</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cannabis days</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.02</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.01&#8211;1.02</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.03</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.02&#8211;1.03</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.01</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>1.00&#8211;1.02</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0015" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cocaine days</td><td align="char" valign="top" rowspan="1" colspan="1">0.98</td><td align="char" valign="top" rowspan="1" colspan="1">0.95&#8211;1.02</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" valign="top" rowspan="1" colspan="1">0.95&#8211;1.04</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">1.01</td><td align="char" valign="top" rowspan="1" colspan="1">0.96&#8211;1.06</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non&#8208;OAT opioid days</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.95</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.94&#8211;0.96</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.93</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.91&#8211;0.94</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.98</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.97&#8211;0.99</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Any injecting</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>23.62</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>19.63&#8211;28.42</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>29.74</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>23.70&#8211;37.32</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">1.26</td><td align="char" valign="top" rowspan="1" colspan="1">1.02&#8211;1.55</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Psychological health</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.92</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.89&#8211;0.96</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.91</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.86&#8211;0.96</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">0.98</td><td align="char" valign="top" rowspan="1" colspan="1">0.93&#8211;1.04</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Physical health</td><td align="char" valign="top" rowspan="1" colspan="1">1.02</td><td align="char" valign="top" rowspan="1" colspan="1">0.99&#8211;1.06</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">1.01</td><td align="char" valign="top" rowspan="1" colspan="1">0.96&#8211;1.06</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">0.99</td><td align="char" valign="top" rowspan="1" colspan="1">0.94&#8211;1.04</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall quality of life</td><td align="char" valign="top" rowspan="1" colspan="1">0.96</td><td align="char" valign="top" rowspan="1" colspan="1">0.92&#8211;1.00</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.88</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.83&#8211;0.92</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0016" ref-type="table-fn">**</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.91</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<bold>0.86&#8211;0.96</bold>
</td><td align="char" valign="top" rowspan="1" colspan="1">
<xref rid="dar13588-note-0015" ref-type="table-fn">*</xref>
</td></tr></tbody></table><table-wrap-foot id="dar13588-ntgp-0002"><fn id="dar13588-note-0013"><p>
<italic toggle="yes">Note</italic>: Bold font indicates statistically significant relationship (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01).</p></fn><fn id="dar13588-note-0014"><p>Abbreviations: aOR, adjusted odds ratio; ATS, amphetamine type substances; CI, confidence interval; OAT, opioid agonist therapy.</p></fn><fn id="dar13588-note-0015"><label>*</label><p>
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01.</p></fn><fn id="dar13588-note-0016"><label>**</label><p>
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001.</p></fn></table-wrap-foot></table-wrap><sec id="dar13588-sec-0021"><label>3.3.1</label><title>
Low frequency use compared to no use
</title><p>People reporting &#8216;low frequency&#8217; use were significantly different to the &#8216;no use&#8217; group on nine of the 16 variables included in the model (Table&#160;<xref rid="dar13588-tbl-0002" ref-type="table">2</xref>). In particular, younger people and those reporting housing stress had significantly greater odds (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) of reporting &#8216;low frequency&#8217; use as opposed to no use. Fewer days' alcohol and opioid use, greater days' cannabis use, and having injected were significantly associated with &#8216;low frequency&#8217; use than non&#8208;ATS use. Clients reporting poor psychological health also had significantly greater odds of being in the &#8216;low frequency&#8217; group as compared with non&#8208;users.</p></sec><sec id="dar13588-sec-0022"><label>3.3.2</label><title>
High frequency use compared to no use
</title><p>A similar pattern of results was observed comparing the &#8216;high frequency&#8217; group to the reference group (who reported no ATS use) (Table&#160;<xref rid="dar13588-tbl-0002" ref-type="table">2</xref>). In particular, people who were younger, experiencing housing stress and recent arrest had significantly greater odds (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) of reporting &#8216;high frequency&#8217; use than &#8216;no use&#8217;. Fewer days' alcohol and non&#8208;OAT opioid use, greater days' cannabis use and having injected was significantly associated with reporting &#8216;high frequency&#8217; ATS, as compared to no use. Poorer psychological health and poorer quality of life was also significantly associated with &#8216;high frequency&#8217; ATS use compared to no use.</p></sec><sec id="dar13588-sec-0023"><label>3.3.3</label><title>
High frequency use compared to low frequency use
</title><p>The two ATS use groups (&#8216;low frequency&#8217; and &#8216;high frequency&#8217;) were the most similar of the three, with fewer significant differences (four) detected of the 16 variables assessed (Table&#160;<xref rid="dar13588-tbl-0002" ref-type="table">2</xref>). In particular, having been arrested and of reporting fewer days of non&#8208;OAT opioid use was associated significantly greater odds (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) of reporting &#8216;high frequency&#8217; compared to &#8216;low frequency&#8217; use.</p></sec></sec></sec><sec sec-type="discussion" id="dar13588-sec-0024"><label>4</label><title>DISCUSSION</title><p>This paper examines the characteristics of clients entering public sector AOD treatment in six districts in NSW over a 3&#8208;year period, with a focus on comparisons between clients according to their recent ATS use (or non&#8208;use) at treatment entry. Almost a quarter (23.5%) of all clients entering AOD treatment had used ATS in the 4&#8201;weeks prior to initial assessment, with 15.2% reporting &#8216;low frequency&#8217; use (1&#8211;12&#8201;days in past 28) and 8.3% reporting &#8216;high&#8217; frequency ATS use (&gt;12&#8201;days in the past 28).</p><p>The study uses data extracted from NSW MDS DATS and ATOP fields that are routinely collected as part of the standardised comprehensive assessment at treatment entry. Together, these provide more detailed data regarding client's substance use, social and health status than previously available from the NSW MDS DATS dataset alone. With almost 14,000 client records described and almost 10,000 records included for further multivariate analysis, it represents the largest analysis focussing on ATS use in clients presenting to AOD services in Australia to date. It also highlights the emerging potential of using routinely collected data from clinical information systems across health services in better understanding the profile and outcomes of clients in AOD services in Australia [<xref rid="dar13588-bib-0025" ref-type="bibr">25</xref>].</p><p>A key finding is the greater severity of social and health problems identified by clients with recent ATS use compared to those presenting for AOD treatment without recent ATS use. The data suggest that on every measure of social function (employment, housing, experience of violence, arrests), psychological health and quality of life (but not physical health), those with recent ATS experienced more severe problems than clients not using ATS at treatment entry. Associations between ATS use and use of other substances were more mixed: clients reporting recent ATS use reported considerably more injecting, and some evidence of more frequent cannabis, but less frequent alcohol or opioid use. More frequent ATS use was associated with poorer quality of life ratings and increased arrests. In summary, AOD clients who reported recent ATS use appeared to have more complex clinical presentations. The increased range of social, mental health and quality of life problems reported by people who used ATS highlights the need for services and clinicians to have the necessary skills, resources and links with other sectors&#8212;including mental health, social and welfare supports&#8212;to address these concerns.</p><p>What factors underpin the association between ATS use and poorer social and health conditions in AOD clients? Several explanations may be suggested. Perhaps this is, at least in part, an artefact of the treatment system. Many authors have commented on how AOD treatment services in Australia have historically had a limited range of interventions to offer people with ATS use, with no effective pharmacotherapies, and have historically been seen as catering for &#8216;drinkers&#8217; and &#8216;heroin users&#8217; [<xref rid="dar13588-bib-0026" ref-type="bibr">26</xref>, <xref rid="dar13588-bib-0027" ref-type="bibr">27</xref>, <xref rid="dar13588-bib-0028" ref-type="bibr">28</xref>, <xref rid="dar13588-bib-0029" ref-type="bibr">29</xref>], such that people using ATS only present for treatment when experiencing more harms. Further, people who experience problems linked to their ATS use, such as dependence, may not identify these issues as sufficiently problematic to warrant seeking treatment [<xref rid="dar13588-bib-0030" ref-type="bibr">30</xref>]. Additionally, this finding may reflect an intrinsic effect of ATS use&#8212;that is, some drugs are more &#8216;harmful&#8217; than others [<xref rid="dar13588-bib-0031" ref-type="bibr">31</xref>, <xref rid="dar13588-bib-0032" ref-type="bibr">32</xref>, <xref rid="dar13588-bib-0033" ref-type="bibr">33</xref>]. Stigma against people who use methamphetamine (which accounts for the majority of ATS use in Australia) may also have been an unfortunate (yet foreseeable) consequence of public media campaigns demonising &#8216;ice&#8217; use over the past decade, further deterring people from seeking treatment at an earlier stage [<xref rid="dar13588-bib-0034" ref-type="bibr">34</xref>, <xref rid="dar13588-bib-0035" ref-type="bibr">35</xref>]. Taken together, this combination of factors may contribute to many people who experience ATS&#8208;related harms deferring treatment entry until problems have escalated [<xref rid="dar13588-bib-0034" ref-type="bibr">34</xref>, <xref rid="dar13588-bib-0035" ref-type="bibr">35</xref>, <xref rid="dar13588-bib-0036" ref-type="bibr">36</xref>]. The evidence we present in this paper suggests that the lives of ATS users seem to be relatively difficult or challenging when they first present to treatment, which in turn suggests that there may be benefit in engaging people in treatment earlier. This reflects existing research showing there is a 5&#8211;10&#8208;year delay in treatment seeking [<xref rid="dar13588-bib-0037" ref-type="bibr">37</xref>], with women in particular facing multiple barriers to access [<xref rid="dar13588-bib-0038" ref-type="bibr">38</xref>]. It is also possible that many people experiencing problems linked to ATS may be appearing elsewhere in the health (e.g., mental health services, emergency departments, primary health) and social (e.g., criminal justice, community services, housing) [<xref rid="dar13588-bib-0039" ref-type="bibr">39</xref>, <xref rid="dar13588-bib-0040" ref-type="bibr">40</xref>] systems but not seeking AOD treatment, highlighting the need for better integration between sectors.</p><p>Only half (46%) of all clients reporting recent ATS use identified ATS as their PDOC, with 23% identifying opioids, and 10% each identifying alcohol, cannabis or &#8216;other&#8217;, emphasising how commonplace it is for many clients entering AOD treatment to be using multiple substances. However, many AOD services are designed around specific drug classes&#8212;for example, Stimulant Clinics, Opioid Treatment Programmes, Cannabis Clinics and a clients' principal drug of concern often guides the treatment delivered in a service. Our findings highlight the importance of individualising and tailoring treatment for each client, supporting clients to address their use of additional substances beyond the &#8216;primary drug&#8217; of concern. Designing services that are flexible and responsive to clients' goals regardless of their PDOC, may reduce treatment access issues for clients through promoting a &#8216;no wrong door&#8217; approach. This may have workforce implications, as clinicians working in an opioid treatment programme or specialist cannabis clinic may require additional training or resources to address ATS use. Further research is required to examine the extent to which ATS use is already addressed in clients seeking AOD treatment where another drug is identified as the PDOC.</p><p>Our study identified a surprisingly high proportion (625 of 2121, 29.5%) of people who identified ATS as their PDOC who did not report any ATS use in the 28&#8201;days prior to entering their treatment episode. This may reflect clients transferring from another treatment service (e.g., a residential rehabilitation), correctional setting, people seeking assistance with relapse prevention, or those referred via court (where the offence and ATS use may have occurred months earlier). This issue has not been identified in the Australian AOD treatment literature previously, and raises the need to better understand why people seek treatment, identify any differences between clients based on their reason/s for seeking treatment, and identify and measure client driven person&#8208;centred treatment goals.</p><sec id="dar13588-sec-0025"><label>4.1</label><title>
Limitations
</title><p>Even with a large data set, the question of generalisability remains. While the proportion of people attending for ATS in our sample (15.3%) is similar to the state&#8208;wide data (16%), our data did not include non&#8208;government organisations and we note that the proportion of public service to non&#8208;government organisations in NSW (62%:38%) is different to other states/territories (1%&#8211;35% public: 65%&#8211;99% non&#8208;government organisations) [<xref rid="dar13588-bib-0007" ref-type="bibr">7</xref>]. This difference should be considered when extrapolating the findings to other locations. A further study limitation is the potential for including participants more than once if they attended two or more different health districts over the study period. Future developments to establish a unique identifier that could be applied across health services (statewide or nationally) would be of clear benefit in this area. Additionally, although training and guides regarding accurate completion of NSW MDS DATS and ATOP data fields are available for all clinicians, it is likely that errors in data collection will have occurred. All data included here are self&#8208;reported by clients, and while the ATOP has been validated in Australian AOD treatment settings, there is always the possibility that some clients have erred in their responses. Moreover, our data represent a 3&#8208;year &#8216;snapshot&#8217; and do not account for changes occurring over a longer period, such as changes in the methamphetamine market [<xref rid="dar13588-bib-0004" ref-type="bibr">4</xref>]. Any cohort study that recruits over a 3&#8208;year period is subject to potential environmental changes over time, including drug market changes, and changes in AOD service systems (e.g., establishment of new services, closure of services, or changes in models of care). Further research to examine whether there are changes over time, for example, by comparing annual cohorts, may be of additional benefit in this area. Finally, we did not examine results by treatment type, or differentiate between Aboriginal and Torres Strait Islander clients and non&#8208;Indigenous clients, which may have yielded valuable additional insights.</p></sec></sec><sec sec-type="conclusions" id="dar13588-sec-0026"><label>5</label><title>CONCLUSIONS</title><p>ATS use is common among clients entering public sector AOD treatment services in NSW and is associated with poorer mental health, quality of life and social conditions than clients without recent ATS use. Less than half of the clients reporting recent ATS use identified ATS as their PDOC and highlights the importance of including responses to ATS use as part of the broader AOD system.</p></sec><sec id="dar13588-sec-0027"><title>AUTHOR CONTRIBUTIONS</title><p>Each author certifies that their contribution to this work meets the standards of the International Committee of Medical Journal Editors.</p></sec><sec id="dar13588-sec-0029"><title>FUNDING INFORMATION</title><p>NCCRED (the funding body) was funded by the Commonwealth Department of Health to support the provision of clinical treatment interventions to people experiencing problems related to their use of methamphetamine and other emerging drugs of concern. The funding for this project is from a seed&#8208;funding grant (unrestricted). None of the authors were involved in the decision to fund the project. Funding allocation was through an open competitive process with an independent peer review panel.</p></sec><sec sec-type="COI-statement" id="dar13588-sec-0030"><title>CONFLICT OF INTEREST</title><p>Two of the investigators (Krista J. Siefried and Nadine Ezard) work for the NCCRED, the organisation funding the study. Investigators Adrian J. Dunlop and Nicholas Lintzeris sit on the board of NCCRED and investigators. Anthony Shakeshaft, Krista J. Siefried, Llewellyn Mills and Michael Farrell are employees of the National Drug and Alcohol Research Centre (UNSW Sydney) which is a member of the NCCRED consortium group. Nicholas Lintzeris, Michael Farrell and Adrian J. Dunlop have received funding from Camurus and Indivior for unrelated research and have served on Advisory Boards for Mundipharma (Nicholas Lintzeris, Adrian J. Dunlop), Indivior (Nicholas Lintzeris) and Camurus (Nicholas Lintzeris) for unrelated projects. Mark Montebello has been an Advisory Board member for AbbVie Australia and Pfizer Australia, both unrelated to this project. Nadine Ezard is employed by St Vincent's Hospital, seconded to UNSW/NCCRED and has no conflicts of interest. Raimondo Bruno has received untied education grants from Mundipharma and Reckitt&#8208;Benckiser for unrelated research. Emma Black, Kristie Mammen, Rachel M. Deacon, Llewellyn Mills, David Reid, Steven Childs and Jennifer Holmes have no competing interests to declare.</p></sec><sec id="dar13588-sec-0031"><title>ETHICS STATEMENT</title><p>Ethics approval, including a consent waiver to use routinely collected clinical data, was obtained from South Eastern Sydney Local Health District Human Research Ethics Committee.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="dar13588-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table S1.</bold> Demographics, risk factors and other substance use in people entering treatment, by frequency of ATS use, July 2016&#8211;June 2019 (<italic toggle="yes">N</italic>&#160;=&#160;13,864)</p><p>
<bold>Table S2.</bold> Welch's analysis of variance and univariate binomial logistic regression results: demographic differences between clients by ATS use frequency</p><p>
<bold>Table S3.</bold> Univariate binomial logistic regression results: Differences between clients by amphetamine type substances use frequency across substance use and injecting</p><p>
<bold>Table S4.</bold> Univariate one&#8208;way and Welch's analysis of variance results: differences between clients by ATS use frequency on health and wellbeing items</p><p>
<bold>Table S5.</bold> Demographics, risk factors and other substance use in people entering treatment, by frequency of ATS use, July 2016&#8211;June 2019 (subsample included in multinomial regression; <italic toggle="yes">N</italic>&#160;=&#160;9981)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DAR-42-389-s001.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dar13588-sec-0028"><title>ACKNOWLEDGEMENTS</title><p>This work was supported by an unrestricted seed&#8208;funding grant from the National Centre for Clinical Research on Emerging Drugs (NCCRED) which is administered by the National Drug and Alcohol Research Centre (UNSW Sydney) and funded by the Australian Government Department of Health. The authors also wish to thank the clients of all participating services and the health information/data managers and their managers, in addition to all project officers, research staff, executive and personal assistants and other administrative staff who provided advice and assistance at various stages throughout the project. Open access publishing facilitated by The University of Sydney, as part of the Wiley &#8208; The University of Sydney agreement via the Council of Australian University Librarians.</p></ack><ref-list id="dar13588-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="dar13588-bib-0001"><label>1</label><mixed-citation publication-type="book" id="dar13588-cit-0001"><collab collab-type="authors">United Nations</collab>
. <source>World Drug Report 2021. Drug market trends: cocaine amphetamine type stimulants (United Nations publication, sales No. E.21.XI.8)</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>United Nations</publisher-name>; <year>2021</year>.</mixed-citation></ref><ref id="dar13588-bib-0002"><label>2</label><mixed-citation publication-type="book" id="dar13588-cit-0002"><collab collab-type="authors">Australian Institute of Health and Welfare</collab>
. <source>National Drug Strategy Household Survey 2019. Drug statistics series no. 32. Cat. no. PHE 270</source>. <publisher-loc>Canberra</publisher-loc>: <publisher-name>AIHW</publisher-name>; <year>2020</year>.</mixed-citation></ref><ref id="dar13588-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dar13588-cit-0003"><string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sara</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>McKetin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Roxburgh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dobbins</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Farrell</surname><given-names>M</given-names></string-name>, et al. <article-title>Crystalline methamphetamine use and methamphetamine&#8208;related harms in Australia</article-title>. <source>Drug Alcohol Rev</source>. <year>2017</year>;<volume>36</volume>:<fpage>160</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">27286742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dar.12426</pub-id></mixed-citation></ref><ref id="dar13588-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dar13588-cit-0004"><string-name name-style="western"><surname>Man</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sisson</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>McKetin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chrzanowska</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dietze</surname><given-names>PM</given-names></string-name>, et al. <article-title>Trends in methamphetamine use, markets and harms in Australia, 2003&#8211;2019</article-title>. <source>Drug Alcohol Rev</source>. <year>2022</year>;<volume>41</volume>:<fpage>1041</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">35604870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dar.13468</pub-id></mixed-citation></ref><ref id="dar13588-bib-0005"><label>5</label><mixed-citation publication-type="book" id="dar13588-cit-0005"><collab collab-type="authors">NSW Health</collab>
. <source>Methamphetamine use and related harms in NSW: surveillance report to December 2019</source>. <publisher-loc>Sydney</publisher-loc>: <publisher-name>NSW Health</publisher-name>; <year>2020</year>.</mixed-citation></ref><ref id="dar13588-bib-0006"><label>6</label><mixed-citation publication-type="book" id="dar13588-cit-0006"><collab collab-type="authors">Australian Institute of Health &amp; Welfare</collab>
. <source>Data table SD9. Alcohol and other drug treatment services in Australia annual report [internet]</source>. <publisher-loc>Canberra</publisher-loc>: <publisher-name>AIHW</publisher-name>; <year>2021</year> Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/alcohol-other-drug-treatment-services-australia" ext-link-type="uri">https://www.aihw.gov.au/reports/alcohol&#8208;other&#8208;drug&#8208;treatment&#8208;services/alcohol&#8208;other&#8208;drug&#8208;treatment&#8208;services&#8208;australia</ext-link></mixed-citation></ref><ref id="dar13588-bib-0007"><label>7</label><mixed-citation publication-type="book" id="dar13588-cit-0007"><collab collab-type="authors">Australian Institute of Health &amp; Welfare</collab>
. <source>Alcohol and other drug treatment services in Australia: annual report</source>. <publisher-loc>Canberra</publisher-loc>: <publisher-name>AIHW</publisher-name>; <year>2021</year>.</mixed-citation></ref><ref id="dar13588-bib-0008"><label>8</label><mixed-citation publication-type="book" id="dar13588-cit-0008"><collab collab-type="authors">Australian Institute of Health &amp; Welfare</collab>
. <source>Alcohol and other drug treatment services in Australia, 2018&#8211;19</source>. <publisher-loc>Canberra</publisher-loc>: <publisher-name>AIHW</publisher-name>; <year>2020</year>.</mixed-citation></ref><ref id="dar13588-bib-0009"><label>9</label><mixed-citation publication-type="book" id="dar13588-cit-0009"><string-name name-style="western"><surname>McKetin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sutherland</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ross</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Najman</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Mamun</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>AL</given-names></string-name>, et al. <source>Methamphetamine treatment evaluation study (MATES): three&#8208;year outcomes from the Sydney site</source>. <publisher-loc>Sydney, Australia</publisher-loc>: <publisher-name>National Drug and Alcohol Research Centre</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="dar13588-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dar13588-cit-0010"><string-name name-style="western"><surname>Bartu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Gawthorne</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Codde</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Holman</surname><given-names>CDAJ</given-names></string-name>. <article-title>Psychiatric comorbidity in a cohort of heroin and amphetamine users in Perth, Western Australia</article-title>. <source>J Subst Use</source>. <year>2003</year>;<volume>8</volume>:<fpage>150</fpage>&#8211;<lpage>4</lpage>.</mixed-citation></ref><ref id="dar13588-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dar13588-cit-0011"><string-name name-style="western"><surname>Lee</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Jenner</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Harney</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cameron</surname><given-names>J</given-names></string-name>. <article-title>Pharmacotherapy for amphetamine dependence: a systematic review</article-title>. <source>Drug Alcohol Depend</source>. <year>2018</year>;<volume>191</volume>:<fpage>309</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">30173086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2018.06.038</pub-id></mixed-citation></ref><ref id="dar13588-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dar13588-cit-0012"><string-name name-style="western"><surname>Siefried</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Acheson</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Lintzeris</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ezard</surname><given-names>N</given-names></string-name>. <article-title>Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review</article-title>. <source>CNS Drugs</source>. <year>2020</year>;<volume>34</volume>:<fpage>337</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">32185696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40263-020-00711-x</pub-id><pub-id pub-id-type="pmcid">PMC7125061</pub-id></mixed-citation></ref><ref id="dar13588-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dar13588-cit-0013"><string-name name-style="western"><surname>Allan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ip</surname><given-names>RHL</given-names></string-name>, <string-name name-style="western"><surname>Kemp</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Snowdon</surname><given-names>N</given-names></string-name>. <article-title>Increased demand for amphetamine treatment in rural Australia</article-title>. <source>Addict Sci Clin Pract</source>. <year>2019</year>;<volume>14</volume>:<fpage>13</fpage>.<pub-id pub-id-type="pmid">30929641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13722-019-0144-6</pub-id><pub-id pub-id-type="pmcid">PMC6442410</pub-id></mixed-citation></ref><ref id="dar13588-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="dar13588-cit-0014"><collab collab-type="authors">HealthStats NSW [Internet]</collab>
. <article-title>NSW Ministry of Health. 2022</article-title>. [cited 28 March 2022]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.healthstats.nsw.gov.au/#/r/101685" ext-link-type="uri">https://www.healthstats.nsw.gov.au/#/r/101685</ext-link>.</mixed-citation></ref><ref id="dar13588-bib-0015"><label>15</label><mixed-citation publication-type="book" id="dar13588-cit-0015"><string-name name-style="western"><surname>Dunlop</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tulloch</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>McKetin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Adam</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wodak</surname><given-names>A</given-names></string-name>. <source>Preliminary evaluation of the NSW stimulant treatment program</source>. <publisher-loc>Sydney</publisher-loc>: <publisher-name>NSW Health</publisher-name>; <year>2008</year>.</mixed-citation></ref><ref id="dar13588-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dar13588-cit-0016"><string-name name-style="western"><surname>McKetin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dunlop</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Holland</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Sutherland</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Salmon</surname><given-names>AM</given-names></string-name>, et al. <article-title>Treatment outcomes for methamphetamine users receiving outpatient counselling from the stimulant treatment program in Australia</article-title>. <source>Drug Alcohol Rev</source>. <year>2013</year>;<volume>32</volume>:<fpage>80</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">22642414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1465-3362.2012.00471.x</pub-id></mixed-citation></ref><ref id="dar13588-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="dar13588-cit-0017"><collab collab-type="authors">Illawarra Shoalhaven Local Health District</collab>
. <article-title>Stimulant Treatment Program (STP) [Internet]. Illawarra Shoalhaven Local Health District; 2019</article-title> [updated nd; cited 23 May 2022]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.islhd.health.nsw.gov.au/services-clinics/stimulant-treatment-program" ext-link-type="uri">https://www.islhd.health.nsw.gov.au/services-clinics/stimulant-treatment-program</ext-link>.</mixed-citation></ref><ref id="dar13588-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dar13588-cit-0018"><string-name name-style="western"><surname>Brener</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lea</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rance</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bryant</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ezard</surname><given-names>N</given-names></string-name>. <article-title>Providing a model of health care service to stimulant users in Sydney</article-title>. <source>Drugs Educ Prev Policy</source>. <year>2018</year>;<volume>25</volume>:<fpage>130</fpage>&#8211;<lpage>7</lpage>.</mixed-citation></ref><ref id="dar13588-bib-0019"><label>19</label><mixed-citation publication-type="book" id="dar13588-cit-0019"><collab collab-type="authors">Centre for Alcohol and Other Drugs</collab>
. <source>NSW minimum data set (MDS) for drug and alcohol treatment services [internet]</source>. <publisher-loc>Sydney, Australia</publisher-loc>: <publisher-name>NSW Health</publisher-name>; <year>2018</year> Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.health.nsw.gov.au/aod/Pages/minimum-data-set.aspx" ext-link-type="uri">https://www.health.nsw.gov.au/aod/Pages/minimum-data-set.aspx</ext-link></mixed-citation></ref><ref id="dar13588-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dar13588-cit-0020"><string-name name-style="western"><surname>Deacon</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Mammen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Holmes</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dunlop</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mills</surname><given-names>L</given-names></string-name>, et al. <article-title>Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations</article-title>. <source>Drug Alcohol Rev</source>. <year>2020</year>;<volume>39</volume>:<fpage>441</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">32395850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dar.13088</pub-id></mixed-citation></ref><ref id="dar13588-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dar13588-cit-0021"><string-name name-style="western"><surname>Ryan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Holmes</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hunt</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Dunlop</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mammen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Holland</surname><given-names>R</given-names></string-name>, et al. <article-title>Validation and implementation of the Australian Treatment Outcomes Profile in specialist drug and alcohol settings</article-title>. <source>Drug Alcohol Rev</source>. <year>2014</year>;<volume>33</volume>:<fpage>33</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">24206571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dar.12083</pub-id></mixed-citation></ref><ref id="dar13588-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dar13588-cit-0022"><string-name name-style="western"><surname>Mammen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mills</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deacon</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dunlop</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Holmes</surname><given-names>J</given-names></string-name>, et al. <article-title>Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions</article-title>. <source>Drug Alcohol Rev</source>. <year>2022</year>;<volume>41</volume>:<fpage>106</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">34189792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dar.13346</pub-id></mixed-citation></ref><ref id="dar13588-bib-0023"><label>23</label><mixed-citation publication-type="book" id="dar13588-cit-0023"><collab collab-type="authors">IBM Corp</collab>
. <source>IBM SPSS statistics for windows, version 26.0</source>. <publisher-loc>Armonk, NY</publisher-loc>: <publisher-name>IBM Corp</publisher-name>; <year>2019</year>.</mixed-citation></ref><ref id="dar13588-bib-0024"><label>24</label><mixed-citation publication-type="book" id="dar13588-cit-0024"><string-name name-style="western"><surname>Lintzeris</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Deacon</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mills</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Holmes</surname><given-names>J</given-names></string-name>, et al. <source>Australian Treatment Outcomes Profile (ATOP) manual 2: research and service evaluation</source>. <publisher-loc>Sydney: AOD Treatment Clinical Outcomes and Quality Indicators Program</publisher-loc>; <year>2021</year>.</mixed-citation></ref><ref id="dar13588-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dar13588-cit-0025"><string-name name-style="western"><surname>Kelly</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Deane</surname><given-names>FP</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Hudson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Keane</surname><given-names>CA</given-names></string-name>, et al. <article-title>Routine outcome measurement in specialist non&#8208;government alcohol and other drug treatment services: establishing effectiveness indicators for the NADAbase</article-title>. <source>Drug Alcohol Rev</source>. <year>2021</year>;<volume>40</volume>:<fpage>540</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">33155315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dar.13191</pub-id></mixed-citation></ref><ref id="dar13588-bib-0026"><label>26</label><mixed-citation publication-type="book" id="dar13588-cit-0026"><string-name name-style="western"><surname>Shearer</surname><given-names>J</given-names></string-name>. <part-title>Treatment responses to problematic methamphetamine use: the Australian experience</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Pates</surname><given-names>R</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Riley</surname><given-names>D</given-names></string-name></person-group>, editors. <source>Interventions for amphetamine misuse</source>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>Wiley&#8208;Blackwell</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="dar13588-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dar13588-cit-0027"><string-name name-style="western"><surname>Vincent</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Schoobridge</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ask</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Allsop</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>R</given-names></string-name>. <article-title>Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia</article-title>. <source>Drug Alcohol Rev</source>. <year>1998</year>;<volume>17</volume>:<fpage>187</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">16203484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09595239800186991</pub-id></mixed-citation></ref><ref id="dar13588-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="dar13588-cit-0028"><string-name name-style="western"><surname>Kenny</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Harney</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Pennay</surname><given-names>A</given-names></string-name>. <article-title>Treatment utilization and barriers to treatment: results of a survey of dependent methamphetamine users</article-title>. <source>Subst Abuse Treat Prev Policy</source>. <year>2011</year>;<volume>6</volume>:<fpage>3</fpage>.<pub-id pub-id-type="pmid">21320347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1747-597X-6-3</pub-id><pub-id pub-id-type="pmcid">PMC3046906</pub-id></mixed-citation></ref><ref id="dar13588-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="dar13588-cit-0029"><string-name name-style="western"><surname>Hando</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Topp</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>W</given-names></string-name>. <article-title>Amphetamine&#8208;related harms and treatment preferences of regular amphetamine users in Sydney, Australia</article-title>. <source>Drug Alcohol Depend</source>. <year>1997</year>;<volume>46</volume>:<fpage>105</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">9246558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0376-8716(97)00051-3</pub-id></mixed-citation></ref><ref id="dar13588-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="dar13588-cit-0030"><string-name name-style="western"><surname>Quinn</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Stoov&#233;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Papanastasiou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dietze</surname><given-names>P</given-names></string-name>. <article-title>An exploration of self&#8208;perceived non&#8208;problematic use as a barrier to professional support for methamphetamine users</article-title>. <source>Int J Drug Policy</source>. <year>2013</year>;<volume>24</volume>:<fpage>619</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">23867050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugpo.2013.05.015</pub-id></mixed-citation></ref><ref id="dar13588-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="dar13588-cit-0031"><string-name name-style="western"><surname>Nutt</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname><given-names>LD</given-names></string-name>. <article-title>Drug harms in the UK: a multicriteria decision analysis</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>:<fpage>1558</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">21036393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(10)61462-6</pub-id></mixed-citation></ref><ref id="dar13588-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dar13588-cit-0032"><string-name name-style="western"><surname>Nutt</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Saulsbury</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Blakemore</surname><given-names>C</given-names></string-name>. <article-title>Development of a rational scale to assess the harm of drugs of potential misuse</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>369</volume>:<fpage>1047</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">17382831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(07)60464-4</pub-id></mixed-citation></ref><ref id="dar13588-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="dar13588-cit-0033"><string-name name-style="western"><surname>Bonomo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Norman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Biondo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Daglish</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dawe</surname><given-names>S</given-names></string-name>, et al. <article-title>The Australian drug harms ranking study</article-title>. <source>J Psychopharmacol</source>. <year>2019</year>;<volume>33</volume>:<fpage>759</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">31081439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0269881119841569</pub-id></mixed-citation></ref><ref id="dar13588-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="dar13588-cit-0034"><string-name name-style="western"><surname>Deen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kershaw</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Newton</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Stapinski</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Birrell</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Debenham</surname><given-names>J</given-names></string-name>, et al. <article-title>Stigma, discrimination and crystal methamphetamine (&#8216;ice&#8217;): current attitudes in Australia</article-title>. <source>Int J Drug Policy</source>. <year>2021</year>;<volume>87</volume>:<elocation-id>102982</elocation-id>.<pub-id pub-id-type="pmid">33126164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugpo.2020.102982</pub-id></mixed-citation></ref><ref id="dar13588-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="dar13588-cit-0035"><string-name name-style="western"><surname>Cumming</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Troeung</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Kelty</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Preen</surname><given-names>DB</given-names></string-name>. <article-title>Barriers to accessing methamphetamine treatment: a systematic review and meta&#8208;analysis</article-title>. <source>Drug Alcohol Depend</source>. <year>2016</year>;<volume>168</volume>:<fpage>263</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">27736680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2016.10.001</pub-id></mixed-citation></ref><ref id="dar13588-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="dar13588-cit-0036"><string-name name-style="western"><surname>Biancarelli</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Biello</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Childs</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Drainoni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Salhaney</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Edeza</surname><given-names>A</given-names></string-name>, et al. <article-title>Strategies used by people who inject drugs to avoid stigma in healthcare settings</article-title>. <source>Drug Alcohol Depend</source>. <year>2019</year>;<volume>198</volume>:<fpage>80</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">30884432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2019.01.037</pub-id><pub-id pub-id-type="pmcid">PMC6521691</pub-id></mixed-citation></ref><ref id="dar13588-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="dar13588-cit-0037"><string-name name-style="western"><surname>Lee</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Harney</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Pennay</surname><given-names>AE</given-names></string-name>. <article-title>Examining the temporal relationship between methamphetamine use and mental health comorbidity</article-title>. <source>Adv Dual Diagn</source>. <year>2012</year>;<volume>5</volume>:<fpage>23</fpage>&#8211;<lpage>31</lpage>.</mixed-citation></ref><ref id="dar13588-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="dar13588-cit-0038"><string-name name-style="western"><surname>Green</surname><given-names>CA</given-names></string-name>. <article-title>Gender and use of substance abuse treatment services</article-title>. <source>Alcohol Res Health</source>. <year>2006</year>;<volume>29</volume>:<fpage>55</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">16767855</pub-id><pub-id pub-id-type="pmcid">PMC6470905</pub-id></mixed-citation></ref><ref id="dar13588-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="dar13588-cit-0039"><string-name name-style="western"><surname>McKetin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shanahan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Lubman</surname><given-names>DI</given-names></string-name>. <article-title>Health service utilisation attributable to methamphetamine use in Australia: patterns, predictors and national impact</article-title>. <source>Drug Alcohol Rev</source>. <year>2018</year>;<volume>37</volume>:<fpage>196</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="pmid">28294443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dar.12518</pub-id></mixed-citation></ref><ref id="dar13588-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="dar13588-cit-0040"><string-name name-style="western"><surname>Cumming</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kinner</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>McKetin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Preen</surname><given-names>D</given-names></string-name>. <article-title>Methamphetamine use, health and criminal justice system outcomes: a systematic review</article-title>. <source>Drug Alcohol Rev</source>. <year>2020</year>;<volume>39</volume>:<fpage>505</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">32212214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dar.13062</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>